Testing the Transportability of the Psychosis Metabolic Risk Calculator in Canada (Quebec): International External Validation Study
Schizophrenia Bulletin · 2026
DOI: 10.1093/schbul/sbaf174 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Schizophrenia Bulletin, 2026. Verfasst von Sébastien Brodeur und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Quebec, G1V 0A6, Canada. Hauptthemen laut MEDLINE: Psychotic Disorders, Metabolic Syndrome, Cardiometabolic Risk Factors. Die Arbeit nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RAPPSODIS Lab: Recherche Axée sur la Personne et la Psychose.
Abstract (Originalsprache)
Background and Hypothesis Cardiometabolic morbidity largely explains premature mortality in people with psychotic disorders and is detectable from psychosis onset. Currently, no accurate cardiometabolic risk prediction tool exists for young people with first-episode psychosis (FEP). The Psychosis Metabolic Risk Calculator (PsyMetRiC) aims to bridge this gap, but its accuracy and potential clinical usefulness in North American populations remain unverified. Study Design The external validity of PsyMetRiC, developed in the United Kingdom to predict the risk of incident metabolic syndrome (MetS) up to 6 years after a FEP, was assessed using the data from the Quebec Psychosis Early Intervention Clinic. PsyMetRiC comprises 2 penalized logistic regression models: a full-model including age, sex, ethnicity, body mass index (BMI), smoking status, prescription of metabolically-active antipsychotic medication, high-density lipoprotein (HDL), and triglyceride concentrations; and a partial-model excluding biochemical predictors. Patients aged 16-35 years, diagnosed with FEP between 2004 and 2023 without pre-existing MetS, and with>12 months follow-up were included. Predictive performance of PsyMetRiC was assessed by discrimination (C-statistic), calibration (calibration plots), and clinical usefulness (decision curve analysis). The race and ethnicity predictor was refined to better represent the North American population. Study Results Among 559 included patients (mean age 24.1 years ±4.1; 22.5% female), 18.2% developed MetS during a mean follow-up of 1.7 ± 1.3 years. Compared with the UK development cohort, the Canadian sample exhibited a higher BMI, lower HDL cholesterol, lower triglycerides, lower blood glucose, and lower systolic blood pressure. Discrimination performance was acceptable (full model C = 0.74, 95% CI, 0.70-0.77; intercept = 0.225; slope = 1.278; partial model C = 0.70, 95% CI, 0.67-0.74; intercept = −0.555; slope = 0.993). After updating the model with a race and ethnicity predictor calibrated to locally representative categories, performance improved slightly (full model C = 0.74, 95% CI, 0.71-0.77; intercept = 0.000; slope = 1.001; partial model C = 0.71, 95% CI, 0.68-0.74; intercept = 0.001; slope = 1.005). Conclusions This study provides the first external validation of PsyMetRiC in a North American sample. Further research is essential before routine clinical implementation, but PsyMetRiC offers promise as a tool for early detection of cardiometabolic risk in early psychosis, guiding personalized treatments to diminish long-term physical health impacts.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry and Neuroscience, Faculty of Medicine, Laval University, Quebec, G1V 0A6, Canada.
- CERVO Brain Research Centre, Quebec, G1E 1T2, Canada.
- Early Psychosis: Interventions and Clinical-Detection (EPIC) Lab, Department of Psychosis Studies, Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, SE5 8AF, United Kingdom.
- University Institute in Mental Health of Quebec, Quebec, G1J 2G3, Canada.
- Faculty of Pharmacy, Laval University, Quebec, G1V 0A6, Canada.
- Department of Psychiatry, University of Oxford, Oxford, OX3 7JX, United Kingdom.
ORCID-Profile: Olivier Corbeil, Laurent Béchard, Maxime Huot-Lavoie, Dominic Oliver, Emanuele F Osimo, Graham K Murray
Förderung
- RAPPSODIS Lab: Recherche Axée sur la Personne et la Psychose
Zitieren
APA
Brodeur, S., Corbeil, O., Béchard, L., Huot-Lavoie, M., Desmeules, C., Oliver, D., De Micheli, A., Osimo, E. F., Upthegrove, R., Khandaker, G. M., Murray, G. K., Lajeunesse-Trempe, F., Cheung, G., Courteau, J., Thériault, C., Roy, M. A., Demers, M. F., & Perry, B. I. (2026). Testing the Transportability of the Psychosis Metabolic Risk Calculator in Canada (Quebec): International External Validation Study. Schizophrenia Bulletin. https://doi.org/10.1093/schbul/sbaf174
Vancouver
Brodeur S, Corbeil O, Béchard L, Huot-Lavoie M, Desmeules C, Oliver D, et al. Testing the Transportability of the Psychosis Metabolic Risk Calculator in Canada (Quebec): International External Validation Study. Schizophrenia Bulletin. 2026. doi:10.1093/schbul/sbaf174
BibTeX
@article{Brodeur2026,
author = {Brodeur, Sébastien and Corbeil, Olivier and Béchard, Laurent and Huot-Lavoie, Maxime and Desmeules, Charles and Oliver, Dominic and De Micheli, Andrea and Osimo, Emanuele F and Upthegrove, Rachel and Khandaker, Golam M and Murray, Graham K and Lajeunesse-Trempe, Fanny and Cheung, Gloria and Courteau, Josiane and Thériault, Chantale and Roy, Marc-André and Demers, Marie-France and Perry, Benjamin I},
title = {Testing the Transportability of the Psychosis Metabolic Risk Calculator in Canada (Quebec): International External Validation Study},
journal = {Schizophrenia Bulletin},
year = {2026},
doi = {10.1093/schbul/sbaf174}
}
EUVIMED